Events | 2021.09.09
Following the Recent Label Expansion, Biohaven's Nurtec ODT Has Come Out Strong in the Migraine Prevention Market, According to Spherix Global Insights
EXTON, Pa., Sept. 9, 2021 /PRNewswire/ -- In May 2021, the FDA approved the label expansion of Biohaven\'s Nurtec ODT for the preventive treatment of episodic migraine, making the gepant the first and only migraine therapy to both prevent and treat migraines. Spherix data show that, three...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]global-insights-301371973.html
